The impact of FLT3 mutation clearance and treatment response after gilteritinib therapy on overall survival in patients with FLT3 mutation–positive relapsed/refractory acute myeloi...

por Altman, Jessica K., Perl, Alexander E., Hill, Jason E., Rosales, Matt, Bahceci, Erkut, Levis, Mark J.
Publicado 2020

Radiation Therapy for Chemotherapy Refractory Gingival Myeloid Sarcoma

por Lee, Daniel Y., Baron, Jonathan, Wright, Christopher M., Plastaras, John P., Perl, Alexander E., Paydar, Ima
Publicado 2021

Molecular profile of FLT3-mutated relapsed/refractory patients with AML in the phase 3 ADMIRAL study of gilteritinib

por Smith, Catherine C., Levis, Mark J., Perl, Alexander E., Hill, Jason E., Rosales, Matt, Bahceci, Erkut
Publicado 2022

Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

por James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut
Publicado 2020

Correction to: Pharmacokinetic Profile of Gilteritinib: A Novel FLT-3 Tyrosine Kinase Inhibitor

por James, Angela Joubert, Smith, Catherine C., Litzow, Mark, Perl, Alexander E., Altman, Jessica K., Shepard, Dale, Kadokura, Takeshi, Souda, Kinya, Patton, Melanie, Lu, Zheng, Liu, Chaofeng, Moy, Selina, Levis, Mark J., Bahceci, Erkut
Publicado 2021

Imatinib-resistance associated with BCR-ABL upregulation is dependent on HIF-1α-induced metabolic reprogramming

por Zhao, Fangping, Mancuso, Anthony, Bui, Thi V., Tong, Xuemei, Gruber, Joshua J., Swider, Cezary R., Sanchez, Patricia V, Lum, Julian J., Sayed, Nabil, Melo, Junia V., Perl, Alexander E., Carroll, Martin, Tuttle, Stephen W., Thompson, Craig B.
Publicado 2010

Dynamic evolution of clonal epialleles revealed by methclone

por Li, Sheng, Garrett-Bakelman, Francine, Perl, Alexander E, Luger, Selina M, Zhang, Chao, To, Bik L, Lewis, Ian D, Brown, Anna L, D’Andrea, Richard J, Ross, M Elizabeth, Levine, Ross, Carroll, Martin, Melnick, Ari, Mason, Christopher E
Publicado 2014

Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients

por Minehart, Janna C., Catania, Christopher, Perry, Linda, Martin, Mary Ellen, Smith, Jacqueline, McCurdy, Shannon R., Pratz, Keith W., Luger, Selina M., Timlin, Colleen, Perl, Alexander E., Schuster, Mindy, Porter, David L, Loren, Alison W., Hexner, Elizabeth O., Frey, Noelle V
Publicado 2021

High Incidence of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia (Ph-like ALL) in Older Adults with B-ALL

por Tasian, Sarah K, Hurtz, Christian, Wertheim, Gerald B, Bailey, Nathanael G, Lim, Megan S, Harvey, Richard C, Chen, I-Ming, Willman, Cheryl L, Astles, Rachel, Zebrowski, Alexis, Reshmi, Shalini C, Li, Marilyn M, Frey, Noelle V, Luger, Selina M, Carroll, Martin, Perl, Alexander E
Publicado 2016

Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia

por Daver, Naval, Perl, Alexander E., Maly, Joseph, Levis, Mark, Ritchie, Ellen, Litzow, Mark, McCloskey, James, Smith, Catherine C., Schiller, Gary, Bradley, Terrence, Tiu, Ramon V., Naqvi, Kiran, Dail, Monique, Brackman, Deanna, Siddani, Satya, Wang, Jing, Chyla, Brenda, Lee, Paul, Altman, Jessica K.
Publicado 2022

Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification

por Peretz, Cheryl A. C., Kennedy, Vanessa E., Walia, Anushka, Delley, Cyrille L., Koh, Andrew, Tran, Elaine, Clark, Iain C., Hayford, Corey E., D’Amato, Chris, Xue, Yi, Fontanez, Kristina M., Roy, Ritu, Logan, Aaron C., Perl, Alexander E., Abate, Adam, Olshen, Adam, Smith, Catherine C.
Publicado 2023

Safety and efficacy of BAY1436032 in IDH1-mutant AML: phase I study results

por Heuser, Michael, Palmisiano, Neil, Mantzaris, Ioannis, Mims, Alice, DiNardo, Courtney, Silverman, Lewis R., Wang, Eunice S., Fiedler, Walter, Baldus, Claudia, Schwind, Sebastian, Pardee, Timothy, Perl, Alexander E., Cai, Charles, Kaulfuss, Stefan, Lagkadinou, Eleni, Rentzsch, Christine, Wagner, Markus, Wilkinson, Gary, Wu, Bingyan, Jeffers, Michael, Genvresse, Isabelle, Krämer, Alwin
Publicado 2020

Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib

por Perl, Alexander E., Hosono, Naoko, Montesinos, Pau, Podoltsev, Nikolai, Martinelli, Giovanni, Panoskaltsis, Nicki, Recher, Christian, Smith, Catherine C., Levis, Mark J., Strickland, Stephen, Röllig, Christoph, Groß-Langenhoff, Marco, Chou, Wen-Chien, Lee, Je-Hwan, Yokoyama, Hisayuki, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon V., Altman, Jessica K.
Publicado 2022

Follow-up of patients with R/R FLT3-mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

por Perl, Alexander E., Larson, Richard A., Podoltsev, Nikolai A., Strickland, Stephen, Wang, Eunice S., Atallah, Ehab, Schiller, Gary J., Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Récher, Christian, Yoon, Sung-Soo, Hosono, Naoko, Onozawa, Masahiro, Chiba, Shigeru, Kim, Hee-Je, Hasabou, Nahla, Lu, Qiaoyang, Tiu, Ramon, Levis, Mark J.
Publicado 2022

Outcomes in Patients with FLT3-Mutated Relapsed/ Refractory Acute Myelogenous Leukemia Who Underwent Transplantation in the Phase 3 ADMIRAL Trial of Gilteritinib versus Salvage Che...

por Perl, Alexander E., Larson, Richard A., Podoltsev, Nikolai A., Strickland, Stephen, Wang, Eunice S., Atallah, Ehab, Schiller, Gary J., Martinelli, Giovanni, Neubauer, Andreas, Sierra, Jorge, Montesinos, Pau, Recher, Christian, Yoon, Sung-Soo, Maeda, Yoshinobu, Hosono, Naoko, Onozawa, Masahiro, Kato, Takayasu, Kim, Hee-Je, Hasabou, Nahla, Nuthethi, Rishita, Tiu, Ramon, Levis, Mark J.
Publicado 2023

S137: IMPACT OF ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN FIRST COMPLETE REMISSION PLUS FLT3 INHIBITION WITH QUIZARTINIB IN ACUTE MYELOID LEUKEMIA WITH FLT3-ITD: RESULTS FRO...

por Schlenk, Richard, Montesinos, Pau, Romero-Aguilar, Antonio, Vrhovac, Radovan, Patkowska, Elżbieta, Kim, Hee-Je, Zak, Pavel, Wang, Po-Nan, Hanyok, James, Liu, LI, Kamel, Yasser Mostafa, Benzohra, Aziz, Lesegretain, Arnaud, Cortes, Jorge, Sekeres, Mikkael A., Dombret, Hervé, Amadori, Sergio, Wang, Jianxiang, Perl, Alexander E., Levis, Mark J., Erba, Harry P.
Publicado 2023

P483: QUANTUM-FIRST TRIAL: FLT3-ITD–SPECIFIC MEASURABLE RESIDUAL DISEASE (MRD) CLEARANCE IS ASSOCIATED WITH IMPROVED OVERALL SURVIVAL

por Levis, Mark J, Erba, Harry P., Montesinos, Pau, Vrhovac, Radovan, Patkowska, Elżbieta, Kim, Hee-Je, Zak, Pavel, Wang, Po-Nan, Connolly Rohrbach, Jaime E., Chang, Ken C.N., Hanyok, James, Liu, LI, Mostafa Kamel, Yasser, Lesegretain, Arnaud, Cortes, Jorge, Sekeres, Mikkael A., Dombret, Hervé, Amadori, Sergio, Wang, Jianxiang, Schlenk, Richard F., Perl, Alexander E.
Publicado 2023

Characteristics and outcome of patients with core-binding factor acute myeloid leukemia and FLT3-ITD: results from an international collaborative study

por Kayser, Sabine, Kramer, Michael, Martínez-Cuadrón, David, Grenet, Justin, Metzeler, Klaus H., Sustkova, Zuzana, Luskin, Marlise R., Brunner, Andrew M., Elliott, Michelle A., Gil, Cristina, Marini, Sandra Casal, Ráčil, Zdeněk, Cetkovsky, Petr, Novak, Jan, Perl, Alexander E., Platzbecker, Uwe, Stölzel, Friedrich, Ho, Anthony D., Thiede, Christian, Stone, Richard M., Röllig, Christoph, Montesinos, Pau, Schlenk, Richard F., Levis, Mark J.
Publicado 2021

Real-world effectiveness of CPX-351 vs venetoclax and azacitidine in acute myeloid leukemia

por Matthews, Andrew H., Perl, Alexander E., Luger, Selina M., Loren, Alison W., Gill, Saar I., Porter, David L., Babushok, Daria V., Maillard, Ivan P., Carroll, Martin P., Frey, Noelle V., Hexner, Elizabeth O., Martin, Mary Ellen, McCurdy, Shannon R., Stadtmauer, Edward A., Paralkar, Vikram R., Bruno, Ximena Jordan, Hwang, Wei-Ting, Margolis, David, Pratz , Keith W.
Publicado 2022

Selective Inhibition of FLT3 by Gilteritinib in Relapsed/Refractory Acute Myeloid Leukemia: a Multicenter, First-in-human, Open-label, Phase 1/2 Study

por Perl, Alexander E., Altman, Jessica K., Cortes, Jorge, Smith, Catherine, Litzow, Mark, Baer, Maria R., Claxton, David, Erba, Harry P., Gill, Stan, Goldberg, Stuart, Jurcic, Joseph G., Larson, Richard A., Liu, Chaofeng, Ritchie, Ellen, Schiller, Gary, Spira, Alexander I., Strickland, Stephen A., Tibes, Raoul, Ustun, Celalettin, Wang, Eunice S., Stuart, Robert, Röllig, Christoph, Neubauer, Andreas, Martinelli, Giovanni, Bahceci, Erkut, Levis, Mark
Publicado 2017